Name | Title | Contact Details |
---|
Ineos Films Inc. is a Delaware City, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iTeknik Holding Corporation is a Commerce Township, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
centennial medical group is a Ellicott City, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ChoiceSpine, LP was founded in December of 2006 in Knoxville, TN. The company is designed to take to the market technically-superior spinal products through a service-focused distribution network. The management team of ChoiceSpine has more than 70 years of industry experience in the areas of research and development, engineering and manufacturing, distribution and sales, financial management and administration. Rick Henson and Marty Altshuler are co-founders and executives of the corporation. They have extensive knowledge of the orthopedic and spinal markets. They are co-principals of ChoiceSpine. They have worked together for 20 years in creating successful healthcare businesses. ChoiceSpine acquired Orthotec, a 40 million dollar company, and now holds the exclusive rights for the U.S. market, several patents and 6 specific spinal conditions. These innovative and proprietary products, when combined with effective procedures, have a successful track record of producing better quality outcomes in surgical patients.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.